65,437 trials
Cardiac Resynchronization Therapy · Chronic Heart Failure
Primary: Changes in a Composite Measure of Clinical Status - New York Heart Association Functional Class — -1.52; -1.0 scores on a scale
Fracture of Shoulder and Upper Arm
Primary: Quality of Analgesia — 2.1; 2.6; 4.1; 4.0 score on a scale
Smoking Cessation
Primary: Percentage of Participants With Abstinence for the Last 4 Weeks of Treatment From Weeks 9-12 — 15.31; 8.72; 5.64 percentage of participants — p=0.0027
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
Type 1 Diabetes Mellitus With Hypoglycemia · Impaired Awareness of Hypoglycemia · Type1diabetes
Primary: % Time Spent in Hypoglycaemia (<3.3mmol/L, 60mg/dL) — -3.0; 1.3 percentage of time <3.3mmol/l — p=0.01
Schizophrenia
Primary: QTcB Change — 416.50; 416.41; 418.39; 423.27 ms
Postoperative Nausea and Vomiting
Primary: Number of Participants With Complete Response (CR), No PONV Symptoms, Nausea — 8; 25; 24; 28 Participants
Metabolic Syndrome · Hypertension
Primary: Change in Insulin Stimulated Glucose Disposal Over 12 Week Study Period — 0.76 mg/kg lean body mass/minute — p=0.2068
Bladder Cancer
Primary: Pathologic Complete Response Rate of Sunitinib — 0 Participants
Obsessive-Compulsive Disorder
Primary: Y-BOCS Change Score (Pre to Post Assessment) — 5.11; 5.09; 0.25 units on a scale
Venous Thromboembolism
Primary: Median Dose of Dalteparin Required to Achieve Prespecified Therapeutic Anti- Factor Xa Level — 125 IU/mL
Bipolar Disorder · Depression
Primary: Health-related Quality of Life, as Measured by the Mental Health Component Score — 38.2; 43.2 score on a scale
Intrinsic Aging of Skin
Primary: Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) — 23; 21 genes
Primary Hyperparathyroidism · Vitamin D Deficiency
Primary: Serum Parathyroid Hormone (PTH) Level
Glioblastoma Multiforme
Primary: Percentage of Subjects With Progression-free Survival — 7.5; 15.0 percentage of subjects